BerGenBio’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

BerGenBio, a biotechnology company, provides contract research and development services to biotechnology and pharmaceutical industries. Read more

Richard S. Godfrey's photo - CEO of BerGenBio

CEO

Richard S. Godfrey

CEO Approval Rating

68/100

Founded:

01/2008

Status:

Est. Annual Revenue
Est. Employees
Sector

Update Industry

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $374.7M a good estimate for BerGenBio's revenue?

Acquisitions

No recent acquisitions found related to BerGenBio

BerGenBio Funding History

$1.3M$10.1M$33.6M$58.8M$61.6M$133.8M

Since BerGenBio was founded in 01/2008, it has participated in 8 rounds of funding. In total BerGenBio has raised $133.8M. BerGenBio's last funding round was on May 2020 for a total of $48.1M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
May 2020
$48.1M
-
Private Placement
Jan 2020
$24M
-
Grant
Jun 2017
$2.9M
Equity
Mar 2016
$25.2M
Equity
Dec 2014
$12.2M
-

Total Funding: $133.8M

Since BerGenBio was founded in 01/2008, it has participated in 8 rounds of funding. In total BerGenBio has raised $133.8M. BerGenBio's last funding round was on May 2020 for a total of $48.1M

Investments

No recent investments found related to BerGenBio

BerGenBio News

August 18, 2020BioSpace

Results for the Second Quarter and First Half of 2020

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhi... See more »
July 28, 2020MarketScreener

Update On Bemcentinib's Involvement in Potential Treatment of COVID-19 Pandemic

(marketscreener.com) BERGEN, Norway, July 28, 2020 /PRNewswire/ -- BerGenBio ASA , a clinical-stage b... See more »
July 21, 2020Pharmabiz

BerGenBio begins patient dosing in trial assessing selective AXL inhibitor bemcentinib in recurrent glioblastoma

BerGenBio ASA, a clinical─stage biopharmaceutical company developing novel, selective AXL kinase inhi... See more »
July 6, 2020MarketScreener

to Present at Digital Novel Coronavirus Investment Forum

(marketscreener.com) BERGEN, Norway, July 7, 2020 /PRNewswire/ -- BerGenBio ASA , a clinical-stage bi... See more »
June 27, 2020Pharmabiz

BerGenBio announces positive interim data from phase II trial of bemcentinib in combo with Keytrudato treat refractory NSCLC

BerGenBio ASA, a clinical─stage biopharmaceutical company developing novel, selective AXL kinase inhi... See more »
June 24, 2020FinanzNachrichten

BerGenBio Announces Change to Presentation Time at Next Gen Immuno-Oncology Congress

BERGEN, Norway, June 24, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmac... See more »
June 23, 2020FinanzNachrichten

BerGenBio to Present at the Upcoming Virtual European Biotech Investor Day 2020

BERGEN, Norway, June 23, 2020 /PRNewswire/ -- BerGenBio, a clinical-stage biopharmaceutical company d... See more »

BerGenBio Press Releases

May 20, 2016EmailWire

Global Pancreatic Ductal Adenocarcinoma Market Research Forecast Report

(EMAILWIRE.COM, May 20, 2016 ) Publisher's, 'Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2... See more »
January 4, 2016Business Wire

Pancreatic Ductal Adenocarcinoma Pipeline Review, H2 2015 - 15 Companies & 27 Drug Profiles

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/8pmg9w/panc... See more »
October 1, 2015PR-INSIDE.COM

"BerGenBio AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile"

(PR-inside.com) BerGenBio AS (BerGenBio) is a biotechnology company that develops drugs for aggressiv... See more »
September 21, 2015PR NEWSWIRE

BGB324 Enhances Immune Checkpoint Inhibitor Efficacy in Preclinical Cancer Models

BERGEN, Norway, September 21, 2015 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an on... See more »
September 11, 2015PR NEWSWIRE

BerGenBio Awarded 2015 Nordic Stars Award

BERGEN, Norway, September 11, 2015 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an on... See more »
September 1, 2015PR NEWSWIRE

BerGenBio Appoints Non-Executive Directors

BERGEN, Norway, September 1, 2015 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an onc... See more »
June 11, 2015BUSINESS WIRE

Liver Fibrosis - Pipeline Review, H1 2015 - Featuring 23 Therapeutics Companies

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/cqjcst/live... See more »

Headquarters

Jonas Lies vei 91

Bergen, Other5006

4753501564

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

BerGenBio, a biotechnology company, provides contract research and development services to biotechnology and pharmaceutical industries. BerGenBio was founded in 01/2008. BerGenBio's headquarters is located in Bergen, Other, NO 5006. It has raised 133....

CEO

BerGenBio's CEO, Richard S. Godfrey, currently has an approval rating of 68%. BerGenBio's primary competitors are

Website

bergenbio.com

Frequently Asked Questions about BerGenBio

  1. When was BerGenBio founded?

    BerGenBio was founded in 01/2008
  2. Who is BerGenBio's CEO?

    BerGenBio's CEO is Richard S. Godfrey
  3. How much revenue does BerGenBio generate?

    BerGenBio generates $374.7M in revenue
  1. How much funding does BerGenBio have?

    BerGenBio has historically raised $133.8M in funding
  2. Where is BerGenBio's headquarters?

    BerGenBio's headquarters is in Bergen Other, NO
  3. How many employees does BerGenBio have?

    BerGenBio has 1,312 employees